These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study. de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776 [TBL] [Abstract][Full Text] [Related]
31. Neurofilament light chain: A novel blood biomarker in patients with ataxia telangiectasia. Veenhuis SJG; Gupta AS; de Gusmão CM; Thornton J; Margus B; Rothblum-Oviatt C; Otto M; Halbgebauer S; van Os NJH; van de Warrenburg BPC; Verbeek MM; Willemsen MAAP Eur J Paediatr Neurol; 2021 May; 32():93-97. PubMed ID: 33878608 [TBL] [Abstract][Full Text] [Related]
32. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M; JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873 [TBL] [Abstract][Full Text] [Related]
33. Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19. Prudencio M; Erben Y; Marquez CP; Jansen-West KR; Franco-Mesa C; Heckman MG; White LJ; Dunmore JA; Cook CN; Lilley MT; Song Y; Harlow CF; Oskarsson B; Nicholson KA; Wszolek ZK; Hickson LJ; O'Horo JC; Hoyne JB; Gendron TF; Meschia JF; Petrucelli L Sci Transl Med; 2021 Jul; 13(602):. PubMed ID: 34131052 [TBL] [Abstract][Full Text] [Related]
34. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Piehl F; Kockum I; Khademi M; Blennow K; Lycke J; Zetterberg H; Olsson T Mult Scler; 2018 Jul; 24(8):1046-1054. PubMed ID: 28627962 [TBL] [Abstract][Full Text] [Related]
35. Blood neurofilament light: a critical review of its application to neurologic disease. Barro C; Chitnis T; Weiner HL Ann Clin Transl Neurol; 2020 Dec; 7(12):2508-2523. PubMed ID: 33146954 [TBL] [Abstract][Full Text] [Related]
36. Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank. Wang X; Shi Z; Qiu Y; Sun D; Zhou H BMC Med; 2024 May; 22(1):192. PubMed ID: 38735950 [TBL] [Abstract][Full Text] [Related]
37. Plasma neurofilament light in Huntington's disease: A marker for disease onset, but not symptom progression. Parkin GM; Corey-Bloom J; Snell C; Castleton J; Thomas EA Parkinsonism Relat Disord; 2021 Jun; 87():32-38. PubMed ID: 33940564 [TBL] [Abstract][Full Text] [Related]
39. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. Gisslén M; Price RW; Andreasson U; Norgren N; Nilsson S; Hagberg L; Fuchs D; Spudich S; Blennow K; Zetterberg H EBioMedicine; 2016 Jan; 3():135-140. PubMed ID: 26870824 [TBL] [Abstract][Full Text] [Related]
40. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. Byrne LM; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RAC; Scahill RI; Tabrizi SJ; Zetterberg H; Langbehn D; Wild EJ Lancet Neurol; 2017 Aug; 16(8):601-609. PubMed ID: 28601473 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]